Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 46% Improvement Relative Risk c19hcq.org Sánchez-Álvarez et al. HCQ for COVID-19 LATE Is late treatment with HCQ beneficial for COVID-19? Retrospective 375 patients in Spain Lower mortality with HCQ (p=0.005) Sánchez-Álvarez et al., Nefrología, doi:10.1016/j.nefroe.2020.04.002 Favors HCQ Favors control
Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN)
Sánchez-Álvarez et al., Nefrología, doi:10.1016/j.nefroe.2020.04.002
Sánchez-Álvarez et al., Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of.., Nefrología, doi:10.1016/j.nefroe.2020.04.002
Apr 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Analysis of 868 patients on renal replacement therapy. Statistically significant reduction in mortality with HCQ for patients on dialysis (OR 0.47, p=0.005).
No statistically significant change was found for transplant patients (the result is not given but likely the sample size is too small - the number of transplant patients was half the number of dialysis patients).
risk of death, 45.9% lower, RR 0.54, p = 0.005, treatment 322, control 53, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sánchez-Álvarez et al., 27 Apr 2020, retrospective, database analysis, Spain, peer-reviewed, mean age 67.0, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: n e f r o l o g i a. 2 0 2 0;4 0(3):272–278 Revista de la Sociedad Española de Nefrología www.revistanefrologia.com Special article Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN)夽 J. Emilio Sánchez-Álvarez a,∗ , Miguel Pérez Fontán b , Carlos Jiménez Martín c , Miquel Blasco Pelícano d , Carlos Jesús Cabezas Reina e , Ángel M. Sevillano Prieto f , Edoardo Melilli g , Marta Crespo Barrios h , Manuel Macía Heras i , María Dolores del Pino y Pino j a Hospital Universitario de Cabueñes, Gijón, Asturias, Spain Servicio de Nefrología, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain c Servicio de Nefrología, Hospital Universitario La Paz, Madrid, Spain d Servicio de Nefrología, Hospital Clínic de Barcelona, Barcelona, Spain e Servicio de Nefrología, Complejo Hospitalario de Toledo, Toledo, Spain f Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain g Servicio de Nefrología, Hospital Universitari de Bellvitge, Barcelona, Spain h Servicio de Nefrología, Consorci Parc de Salut Mar de Barcelona, Barcelona, Spain i Servicio de Nefrología, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Canarias, Spain j Servicio de Nefrología, Complejo Hospitalario Torrecárdenas, Almería, Spain b a r t i c l e i n f o a b s t r a c t Article history: Introduction: The recent appearance of the SARS-CoV-2 coronavirus pandemic has had a Received 15 April 2020 significant impact on the general population. Patients on renal replacement therapy (RRT) Accepted 22 April 2020 have not been unaware of this situation and due to their characteristics they are especially Available online 27 April 2020 vulnerable. We present the results of the analysis of the COVID-19 Registry of the Spanish Society of Nephrology. Keywords: Material and methods: The Registry began operating on March 18th, 2020. It collects epi- SARS-CoV-2 demiological variables, contagion and diagnosis data, signs and symptoms, treatments and Registry outcomes. It is an online registry. Patients were diagnosed with SARS-CoV-2 infection based Renal replacement therapies on the results of the PCR of the virus, carried out both in patients who had manifested com- Spain patible symptoms or had suspicious signs, as well as in those who had undergone screening Spanish Society of Nephrology after some contact acquainted with another patient. DOI of original article: https://doi.org/10.1016/j.nefro.2020.04.002. 夽 Please cite this article as: Sánchez-Álvarez JE, Fontán MP, Martín CJ, Pelícano MB, Reina CJ, Prieto ÁM, et al. Situación de la infección por SARS-CoV-2 en pacientes en tratamiento renal sustitutivo. Informe del Registro COVID-19 de la Sociedad Española de Nefrología (S.E.N.). Nefrologia. 2020;40:272–278. ∗ Corresponding author. E-mail addresses: jesastur@hotmail.com, jesastur@gmail.com (J.E. Sánchez-Álvarez). 2013-2514/© 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrologı́a. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 273 n e f r o l o g i a. 2 0 2 0;4 0(3):272–278 Results: As of April 11, the Registry had data on 868 patients, from all the Autonomous Communities. The most represented form of RRT is in-center hemodialysis (ICH) followed by transplant patients. Symptoms are similar to the general..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit